IMHO CE & TGA is a given as these regulatory bodies will be focusing on the fantastic Australian breathe easy results not the SmartCough C2 results out of the US. This will open the door to some Asian countries for us to sell our products into too like Singapore I believe. We should be granted CE & TGA approval for all six respiratory conditions. This will allow us to sell into a very large market bigger than that of the US. Once the adult results are released (any day now) the company will again apply for a CE submission followed by TGA, similar to the process being conducted now for the kids..
The share price had a spread of about 10 cents up from previous day's close on the back of the positive announcement from memory on the positive breath easy children results.
When one considers the overall population "The EU covers over 4 million km² and has 508 million inhabitants - the world's third largest population after China and India. By surface area, France is the biggest EU country and Malta the smallest."
With a total of around 60 million under the age of 14:
....Our potential market within the European union dramatically increases around 750% when or if positive Austraian adult results are obtained over the coming days... what will that do to the share price spread on the back of positive Australian adult results on the day... Hmmmm one can only guess....
By the way I'm looking forward to any commentary coming from the company relating to the recent Asian presentations. It would be excellent news to find a partner there so that we can conduct studies through Asia and go through their regulatory body - CFDA.
I strongly believe we have a good chance of obtaining FDA clearances for at least three of our main respiratory diseases that would bring in the most revenue. These thoughts of mine will be reinforced on the back of an announcement stating that filing has taken place with Experian group, our consultants which is still due to be announced before the end of this quarter. Experian groups track record for Success speaks volumes if they're backing us then for me it's almost a given for three respiratory conditions to be approved in the US (FDA) as well...
also looking forward to any developments from the scientific advisory meetings scheduled early next month giving us a insight and breakdown of the study by the principal investigator. if nothing is discussed there, there is still a couple of other events scheduled where our results could be discussed like at the Massachusetts general children's Hospital presentations/upcoming events. Meanwhile I'm sure the principal investigator and our scientific advisory board are busy discussing the findings in detail by preparing this information into a medical journal for publication. Perhaps when discussed to the public or when publication is released ResApp will then release a breakdown of details showing the accuracy when the doctors were both in agreement for example...
Very interesting times ahead for this company!
Cheers
Red bar
RAP Price at posting:
7.3¢ Sentiment: Buy Disclosure: Held
(20min delay)
